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In Brief
Proteasome inhibition by small molecules
constitutes a successful therapy for
blood cancer. Huber et al. structurally and
biochemically analyzed mutant yeast
proteasomes, which are resistant to the
drug bortezomib. The results
demonstrate that the compound
carfilzomib overcomes the three
unraveled mechanisms of mutation-
mediated drug resistance best.
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Inhibition of the 20S proteasome by bortezomib
(Velcade) constitutes a successfully applied therapy
for blood cancer. However, emerging resistance re-
stricts its medicinal use. For example, mutations in
the proteolytically active b5-subunit of the protea-
some, the main target of inhibitors, were reported
to impair drug binding and thus to reduce therapeutic
efficacy. Using yeast as amodel system, we describe
here a systematic evaluation of these mutations by
cell growth analysis, proteasome inhibition assays,
and X-ray crystallography. The 11 mutants examined
display decreased proliferation rates, impaired pro-
teolytic activity, and marked resistance to bortezo-
mib as well as the a0,b0-epoxyketone inhibitors
carfilzomib (Kyprolis) and ONX 0914, while the sec-
ond-generation compound carfilzomib was the least
affected. In total, 49 proteasome X-ray structures,
including structural data on proteasome-carfilzomib
complexes, reveal three distinct molecular mecha-
nisms that hamper both drug binding and natural
substrate turnover to an extent that is still compatible
with cell survival.
INTRODUCTION
Eukaryotic proteasomes account for the majority of intracellular
nonlysosomal protein degradation and tightly regulate pivotal
biological processes, ranging from cell proliferation to antigen
generation (Ciechanover, 1994). The barrel-shaped 20S core
particle (CP) bears three proteolytically active subunits, b1, b2,
and b5, which exert caspase-like, trypsin-like, and chymo-
trypsin-like activities, respectively. Their inhibition by small mol-
ecules such as the boronic acid inhibitor bortezomib (1, Velcade;
Figure 1A; Figure S1B available online) is cytotoxic and thera-
peutically effective in hematopoietic malignancies (Huber and
Groll, 2012; Kane et al., 2003; Kisselev et al., 2012). Bortezomib
is highly potent and inactivates the proteasomal active site by a
covalent but slowly reversible binding mode. By prolonging the
lifetime of countless patients, bortezomib soon became a block-
buster drug, and additional applications such as therapy for solidStructure 23, 40tumors and prevention of transplant rejection are being explored
(Deming et al., 2013; Raghavan et al., 2010). Despite its over-
whelming success, bortezomib causes severe adverse effects
(Cavaletti and Jakubowiak, 2010), such as neuropathy, which
presumably result from off-target activities (Arastu-Kapur et al.,
2011). Furthermore, as with numerous anticancer drugs and
antibiotics, patients often acquire resistance (Cheriyath et al.,
2007; Kumar and Rajkumar, 2008), but the molecular mecha-
nisms underlying the nonresponsiveness to bortezomib are still
controversially discussed. Among other suggested mechanisms
(Chauhan et al., 2003; Gutman et al., 2009; Leung-Hagesteijn
et al., 2013; Shaughnessy et al., 2011; Shuqing et al., 2011; Ver-
brugge et al., 2012), adaptive mutations around the b5 active site
of the proteasome, the preferred binding site of bortezomib,
were identified in cell culture models to cause resistances (de
Wilt et al., 2012; Franke et al., 2011; Lu¨ et al., 2008, 2009; Oerle-
mans et al., 2008; Ri et al., 2010; Suzuki et al., 2011). Although
mammalian cells express three types of 20S proteasomes
with unique sets of proteolytically active b subunits, namely
the constitutive proteasome (cCP; b1c, b2c, and b5c), the
immunoproteasome (iCP; b1i, b2i, and b5i), and the thymopro-
teasome (tCP; b1i, b2i, and b5t) (Groettrup et al., 2010; Murata
et al., 2008), bortezomib-resistance-associated mutations have
so far been identified only in the b5c subunit of the cCP.
In an effort to elucidate the molecular mechanisms of ac-
quired resistance to bortezomib, we structurally and biochemi-
cally analyzed 11 genetically engineered variants of the yeast
20S proteasome (yCP) through X-ray crystallography and inhibi-
tion assays. The conservation of the affected residues in the
yCP, the overall similar fold of yeast and mammalian protea-
some subunits (root-mean-square deviation [rmsd] <0.72 A˚) as
well as the identical binding mode of proteasome inhibitors to
yeast and mammalian CPs justify the use of Saccharomyces
cerevisiae as a model organism for mutagenesis studies (Huber
et al., 2012). Incorporation of the described resistance-confer-
ring mutations into the yeast b5 (yb5) subunit impairs cell growth
and attenuates the chymotrypsin-like activity of the mutant
yCPs as well as their affinity for bortezomib. Notably, the mutant
proteasomes also exhibit marked cross-resistance to the a0,b0-
epoxyketone inhibitor carfilzomib (2, Figure 1A; Kyprolis) and to
its analogue ONX 0914 (3, Figures 1A and S1B). Like bortezo-
mib, the second-generation proteasome inhibitor carfilzomib,
recently licensed for the second-line treatment of multiple
myeloma, equally targets the b5 subunits of both cCP and iCP
(Demo et al., 2007; Fostier et al., 2012). In contrast, ONX 09147–417, February 3, 2015 ª2015 Elsevier Ltd All rights reserved 407
Figure 1. Chemical Structure and Binding Mode of the Proteasome Inhibitor Carfilzomib
(A) Chemical structures of proteasome inhibitors used in this study.
(B) Stereo illustration of the 2FO  FC electron density map (gray mesh; contoured at 1s) for carfilzomib (green) bound to the b5 active site of the WT yCP. The
active site Thr1 is marked in black. Important interactions are indicated by black dotted lines. Amino acids are labeled by the one-letter code and numbered
according to the sequence alignment with the proteasomal b subunit of Thermoplasma acidophilum (Lo¨we et al., 1995).
See also Figure S1.is a selective inhibitor of the b5i subunit of the iCP and preclinical
studies are currently exploring its potential as an immunosup-
pressant (Basler et al., 2010; Ichikawa et al., 2011; Muchamuel
et al., 2009; Nagayama et al., 2012). Our crystallographic data
on 11 mutant yCPs in their ligand-free and inhibitor-bound
states dissect the molecular mechanisms of mutation-mediated
insensitivity toward proteasome inhibitors in general and eval-
uate the potential of carfilzomib and ONX 0914 to overcome
these.
RESULTS
Crystal Structure of the yCP inComplexwithCarfilzomib
Carfilzomib was granted approval in 2012 for the treatment of
multiple myeloma as a second-line drug. However, no struc-
tural information on its binding mode to the proteasome has
so far been available. In order to complete the collection of
X-ray structures on prominent proteasome inhibitor complexes,
among them bortezomib (Groll et al., 2006) and ONX 0914
(Huber et al., 2012), we determined the co-crystal structures
of the yCP with carfilzomib. The tetrapeptide moiety of carfilzo-
mib adopts an antiparallel b sheet in the b5 substrate binding
channel (Figure 1B). The N-morpholine cap of carfilzomib,
which induces a kink in the ligand’s peptide backbone, un-
dergoes van der Waals interactions with Ala22 (b5), Trp25
(b5) and His98 (b6). The P4 homophenylalanine occupies the
S4 pocket formed by the adjacent subunit b6 and is stabilized408 Structure 23, 407–417, February 3, 2015 ª2015 Elsevier Ltd All rby hydrophobic interactions with Pro94 and Val116 (3.7–4.3 A˚;
Figure 1B). The conservation of Pro94 and Val116 in the human
b6 subunit, which is incorporated into cCPs as well as iCPs, at
least partly explains why carfilzomib equally targets both types
of CPs. Although Arg91 (b6) is not perfectly positioned to
electrostatically interact with the p system of the homopheny-
lalanine moiety, it may have some stabilizing effects (Figure 1B).
The N-morpholine cap of carfilzomib undergoes van der Waals
interactions with Ala22 (b5), Trp25 (b5), and His98 (b6). Notably,
His98 is also weakly hydrogen bonded to the oxygen atom
of the morpholine N-cap and the N-terminal carbonyl oxygen
of the inhibitor backbone (3.2–3.4 A˚). The corresponding
Tyr98 of the human b6 subunit may also be engaged in interac-
tions with the morpholine N-cap, thereby providing additional
anchoring.
The yCP: A Model System for High-Throughput
Structural and Biochemical Evaluation of Proteasome
Mutants
The overall fold of the catalytically active proteasome subunits
and the binding mode of inhibitors to the proteasome are
conserved from yeast to mammals (Huber et al., 2012). Despite
species-specific differences in the amino acid (aa) sequence
(e.g., Q53S and T57R in b5 as well as H98Y in b6), which may
affect inhibitor binding, the yCP turned out to be a suitable model
system for studying the proteasome and its interaction with
inhibitory compounds (Borissenko and Groll, 2007). In addition,ights reserved
Figure 2. Growth Analysis and Activity
Assay of WT and Mutant Yeasts
(A) Serial dilutions of yeast cells were spotted on
YPD plates and grown for 2 days either at 30C or
37C.
(B) In situ test for ChT-L activity of WT and mutant
yCPs. The pre2-2 mutant (pre2-A49V chromoso-
mally expressed), which is defective in ChT-L
activity (Heinemeyer et al., 1993), served as a
negative control and WT yeasts (WCG4a and
pre2D::HIS3 [pRS315-PRE2] as positive controls.
Intense pink coloring is indicative ofWT-like ChT-L
activity toward the substrate Z-GGL-pNA, while
pale yeasts suffer from proteolytic defects.
See also Figure S2.genetic manipulation of yeast offers the possibility of creating
mutant eukaryotic proteasomes for structural analyses with
reasonable time and effort. We therefore incorporated the
mutations that were reported to be associated with resistance
to bortezomib into the yeast proteasome subunit b5 and exam-
ined their impact on the structural integrity of the active site,
enzymatic activity, and inhibitor binding. The structural analysis
of b5mutant yCPs allowed us to identify three different molecular
mechanisms for bortezomib resistance, according to which the
created mutants are grouped.
The first set consists of variations of aa 49 and aa 50 (A49S/T/
V, A50V), the second set contains mutations of the S1 pocket-
forming Met45 (M45A/T/V/I), and the third set comprises aa
mutations C52F and C63F, which are located in proximity to
the ChT-L substrate binding channel (Franke et al., 2011; Lu¨
et al., 2009; Oerlemans et al., 2008; Suzuki et al., 2011).
Even though all mutant yeast strains were viable at 30C, some
were retarded in growth. These defects were more pronounced
at 37C due to temperature-induced protein misfolding and ag-
gregation. Mutants with limited proteasome function fail to cope
with this increased working load and grow more slowly (Figures
2A and S2A). The ChT-L activity of mutant proteasomes was as-
sayed qualitatively with an in situ overlay test using the chromo-
genic substrate carboxybenzyl-Gly-Gly-Leu-para-nitroanilideStructure 23, 407–417, February 3, 2015(Z-GGL-pNA; Figure 2B). Hydrolysis of
the fluorogenic model substrate N-succi-
nyl-Leu-Leu-Val-Tyr-7-amino-4-methyl-
coumarin (Suc-LLVY-AMC) by purified
proteasomes was used to quantify
changes in activity between mutant and
wild-type (WT) yCPs (Figure S2B) and to
evaluate the susceptibility of mutant
yCPs to the prevalent proteasome inhibi-
tors bortezomib, carfilzomib, and ONX
0914 (Figure 3). Suc-LLVY-AMC is
cleaved at higher rates compared with
Z-GGL-AMC (Kisselev and Goldberg,
2005) and hence is the standard peptide
to monitor proteasomal ChT-L activity
in vitro. For in vivo or in situ analysis of
proteasome activity, however, Z-GGL-
pNA is more appropriate, as the pNA
analogue of Suc-LLVY-AMC can also beprocessed by other proteases with ChT-L activity, such as
carboxypeptidase Y (Kunugi et al., 1985).
All mutant proteasomes were crystallized and their X-ray
structures were evaluated for peculiarities in and around the b5
active site (Figures 4, 5, S4, and S5).
Mutation of Ala49 in Subunit b5 Restricts the Access
to the Active Site
Sequence analysis of bortezomib-resistant human cell lines
identified the mutations A49T, A49V, and A49T_A50V in the pro-
teasome subunit b5c as a source of drug resistance (Franke
et al., 2011; Lu¨ et al., 2008, 2009). To elucidate the molecular
reason for their nonresponsiveness to bortezomib, we created
the yeast mutants A49T, A49V, and A49T_A50V as well as
A49S and A50V.
The mutants A49T and A49V grow likeWT yeast at the permis-
sive temperature of 30C but are markedly retarded in growth
under stress conditions (37C). By contrast, the double mutant
A49T_A50V shows a pronounced growth defect even at 30C
and is not viable at 37C (Figures 2A and S2A). All three mutants
fail to cleave the chromogenic substrate Z-GGL-pNA (Figure 2B)
and their ChT-L activity toward Suc-LLVY-AMC is attenuated by
about 60%–70% compared with WT yCPs (Figure S2B). As
anticipated, the purified mutant yCPs display marked resistanceª2015 Elsevier Ltd All rights reserved 409
Figure 3. In Vitro Inhibition Assays
Purified mutant (mt) yeast proteasomes were tested for the susceptibility of their ChT-L activity to inhibition by bortezomib, carfilzomib, and ONX 0914 using the
substrate Suc-LLVY-AMC. IC50 values were determined in triplicate; standard deviations are indicated as black bars. The ratio IC50(mt)/IC50(WT), a measure of
inhibitor resistance, is given. Large values indicate strong drug resistance. Note that IC50 values depend on time and enzyme concentration. Proteasomes (final
concentration: 66 nM) were incubated with inhibitor for 45 min before substrate addition (final concentration 200 mM).
See also Figure S3.to proteasome inhibitors, in particular to bortezomib (up to 27-
fold; Figure 3). Even though the yCP b5 mutants A49S and
A50V show normal proliferation rates at both temperatures
tested (Figures 2A and S2A), their ChT-L activity is substantially
reduced (by about 50%–60%) compared with WT yeast (Figures
2B and S2B). In addition, the A49S mutant also conveys drug
resistance, whereas the A50V mutation impairs binding of li-
gands only to a minor extent (Figure 3). In conclusion, substitu-
tion of Ala49, which is part of the S1 pocket of the substrate
binding channel and crucial for interactions with natural and syn-
thetic ligands (Groll et al., 1997), is more harmful thanmutation of
Ala50, the side chain of which is not directly engaged in binding
of inhibitors.
Next, we structurally characterized all mutant yCPs by X-ray
crystallography. The mutation A50V triggers no structural
changes in the b5 active site (Figures 5A, S5A, and S5B)
and thus altered proteasome dynamics may account for the
observed decrease in proteolytic activity and the mild drug
resistance. Several structural explanations can, however, be410 Structure 23, 407–417, February 3, 2015 ª2015 Elsevier Ltd All rprovided for the more severe phenotype caused by the single
mutants A49S, A49T, and A49V: (1) aa larger than Ala shift the
position of the sulfur atom of Met45 by at least 0.9 A˚ (Figures
4A–4D) and thereby attenuate important hydrophobic interac-
tions with ligands during their binding process (Huber et al.,
2012); (2) they significantly narrow the substrate binding channel
and hamper the access of substrates and inhibitors to the ChT-L
active site (Figure 5A); (3) in the mutants A49V and A49T, the
hydrogen bond between aa 49NH and the N-terminal carbonyl
oxygen of bortezomib is elongated by up to 0.2 A˚ compared
with WT yCPs, which may destabilize the ligand in the substrate
binding channel (Figure 5B).
Based on these results, the doublemutant A49T_A50V and the
single mutant A49T are expected to display similar phenotypes.
Even though this holds true for the in vitro affinities to inhibitors
(Figure 3) and the impairment in ChT-L activity toward synthetic
tri- and tetrapeptides (Figures 2B and S2B), the double mutant
A49T_A50V suffers from a more severe growth defect than the
single mutant A49T (Figures 2A and S2A). An explanation forights reserved
this synergistic effect is provided by conformational alterations in
the loop region Met45-Ala50 that are present in the double
mutant A49T_A50V but absent in the corresponding single mu-
tants (Figures 4B, 4C, S4B, S4C, and S5A). This structural
change shifts the sulfur atom of Met45 by 3.1 A˚, leading to an
iCP-like conformation with a spacious S1 pocket (Huber et al.,
2012). More importantly, however, the loop rearrangement ob-
structs the substrate binding channel and disturbs access of
both natural substrates and synthetic ligands to the active site
Thr1 (Figure 5A). Structural data on the A49T_A50V mutant in
complex with bortezomib show that the hydrogen bond between
T49NH and the N-terminal carbonyl oxygen of the backbone of
the ligand is broken (distance 3.2 A˚ in the WT versus 4.6 A˚ in
the mutant), consequently preventing the formation of an anti-
parallel b sheet in the b5 substrate binding channel (Figures
4C, S4C, 5B, and S5B). This destabilization decreases the affin-
ity of the dipeptide bortezomib (24-fold), which is a slowly revers-
ible binder, lacks a defined P3 site, and undergoes only a few
interactions with the protein binding pockets. In contrast, the
tri- and tetrapeptidic backbones of ONX 0914 and carfilzomib,
respectively, form extended antiparallel b sheets in the substrate
binding channel and are far better stabilized by the surrounding
protein than bortezomib (factor of resistance 5–15). In addition,
their irreversibly acting epoxyketone head group provides
enough driving force in terms of binding energy to overcome
the conformational restraints provided by the structural changes.
Although small synthetic model peptides are cleaved at roughly
similar rates by the mutants A49T and A49T_A50V (Figures 2B
and S2B), natural peptide substrates may bind to the double
mutant with much lower affinity compared with the A49T mutant
or may be differently processed by both proteasomes. This is
most probably the ultimate cause of the severe yeast cell growth
defects.
The S1 Pocket-FormingMet45 of Subunit b5 Is Essential
for High-Affinity Binding of Natural and Synthetic
Ligands
Met45 forms the bottom of the S1 pocket in the b5 substrate
binding channel and therefore is the key determinant of the
ChT-L activity (Groll et al., 1997). It is expected to form a steric
barrier to large P1 side chains, as its conformation changes
upon binding of bulky ligands to the active site Thr1 (Huber
et al., 2012). Mutations of Met45 to valine or isoleucine were
identified after long-term exposure of cell cultures to high doses
of bortezomib (Franke et al., 2011). We introduced both aa
mutations and the mutations M45A and M45T into the yCP and
analyzed them biochemically and structurally.
The mutant yeasts show no growth phenotypes at 30C but,
under stress conditions (37C), the proliferation rate of the
mutant M45V is delayed (Figures 2A and S2A). Hence, yeast
viability does not strictly depend on Met45 but Val45 appears
to harm proteasome activity. In situ analysis of the ChT-L activity
reveals that both substitutions M45V and M45I fail to cleave the
chromogenic substrate Z-GGL-pNA, whereas the proteolytic
activity of M45A andM45T is reduced to only aminor extent (Fig-
ure 2B). In vitro activity tests using the substrate Suc-LLVY-AMC
further corroborate these results (Figure S2B). In line with their
reported resistance to bortezomib, M45V and M45I yCPs are
highly insensitive to the boronic acid (up to 27-fold) and displayStructure 23, 40significant cross-resistance to the a0,b0-epoxyketones carfilzo-
mib and ONX 0914 (up to 12-fold increased half maximal inhibi-
tory concentration [IC50]). By contrast, the mutants M45A and
M45T are less resistant to proteasome inhibition (up to 7-fold;
Figure 3).
From a structural point of view, mutation of Met45 to smaller
side chains was expected to allow access to the S1 specificity
pocket without structural changes. However, in agreement
with a recent study (Arciniega et al., 2014), our crystallographic
data show that inhibitors also induce conformational shifts in
b5 subunits in which Met45 has been replaced by Ala/Thr/Val
or Ile and are hence independent of Met45. The Cb atoms of
Ala45 and Thr45 are moved by up to 0.9 A˚ upon ligand binding,
whereas those of Val45 and Ile45 are shifted up to 1.5 A˚ and
2.0 A˚, respectively (Figures 4E–4H and S4E–S4H). This observa-
tion may reflect the more unfavorable impact of Val45 and Ile45
on proteasome activity.
Furthermore, we checked the mutant X-ray structures ob-
tained for steric hindrance or insufficient stabilization of ligands.
Compared with the WT yCP, the M45A mutant is moderately
drug resistant because the S1 pocket provides fewer hydropho-
bic interactions with the P1 side chain of the ligand. Substitution
of Met45 with Val45 is also not advantageous as its Cg pro-
trudes into the S1 pocket and thereby sterically hinders binding
of inhibitors and substrates (distance <2.4 A˚) rather than stabi-
lizing them. Whereas Met45 can undergo smooth rotation, this
is not possible for Val45. Compared with Val45, incorporation
of Ile45 causes a less severe growth phenotype. Since the Cd
of Ile45 is engaged in hydrophobic interactions with Ile35
(3.5–4.0 A˚), it does not further hinder ligand docking. In the
ligand bound state, the Cd of Ile45 somehow mimics Met45
and further stabilizes the P1 side chain of the ligand by hydro-
phobic interactions (3.2–4.1 A˚), which cannot be provided by
Cg only (Figures 4E–4H and S4E–S4H). This may explain the
attenuated growth defect of the mutant M45I versus M45V.
The exchange M45T is supposed to cause similar or even
worse effects on proteasome activity than Val45. However,
the mutant M45T surprisingly displays only modestly reduced
ChT-L activity and affinity for carfilzomib (5-fold) as well as bor-
tezomib (3-fold) (Figures 2B and 3). X-Ray structures show that
Thr45Og is hydrogen bridged (2.6 A˚) to its own carbonyl oxygen
atom of the main chain and this interaction persists even when
bortezomib, carfilzomib, or ONX 0914 is bound (2.6–2.8A˚; Fig-
ures 4F and S4F). Even though the polar interactions of the
carbonyl oxygen with the hydroxyl group of Thr45 cannot be
provided by the Cg atom of Val45 or Ile45, it can hardly explain
the alleviated phenotype of Thr45 compared with Val45.
Notably, Thr45 is strictly conserved in the tCP subunit b5t,
which is known to exert strongly reduced ChT-L activity
compared with standard proteasomes (Murata et al., 2007).
Thus, our results indicate that this is at least in part caused
by the aa exchange M45T.
Resistance to Proteasome Inhibitors Is Triggered
by the b5 Mutation C52F but Not C63F
The mutations C63F and C52F were both reported to mediate
resistance to the canonical proteasome inhibitor bortezomib
(de Wilt et al., 2012; Franke et al., 2011; Suzuki et al., 2011),
even though the respective aa do not interact with substrates7–417, February 3, 2015 ª2015 Elsevier Ltd All rights reserved 411
(legend on next page)
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Figure 5. Narrowing of the b5 Substrate Binding Channel by Mutation of Ala49
(A) Mutations of Ala49 restrict the access to the active site Thr1 of subunit b5. Surface representations of the b5 substrate binding channel ofWT andmutant yCPs
are depicted. Mutations are colored in cyan; the active site Thr1 is shown in black. Ala49 and Ala50, the sites of mutation are highlighted in theWT yCP by dotted
circles.
(B) Ribbon drawings of the b5 active site of mutant yCPswith bortezomib (green) bound to the active site Thr1 (black). Mutations are highlighted in cyan. Hydrogen
bonds required for the antiparallel b-sheet formation of the ligand in theWT substrate binding channel are indicated by black dotted lines. Notably, the distance of
the hydrogen bond required to stabilize the N-terminal peptide bond of bortezomib is enlarged (A49T, A49V) or even broken (A49T_A50V).
See also Figure S5.or ligands. Yeasts carrying the mutation C63F do not differ from
WT with respect to growth (Figures 2A and S2A), processing of
the Z-GGL-pNA and Suc-LLVY-AMC substrate (Figures 2B
and S2B), and affinity for proteasome inhibitors (Figure 3). Crys-
tallographic analysis confirmed the incorporation of themutation
into yCP but revealed no structural peculiarities (Figures 4J and
S4J). In conclusion, the mutation C63F does not confer drug
resistance with the settings tested in yeast.Figure 4. Structural Aspects of Bortezomib-Resistant Mutant Yeast Pr
(A-J) Superpositions ofWT (gray) andmutant (yellow) b5 subunits are shown in the
superpositions of mutant b5 subunits in their ligand-free (gray) and bortezomib-bo
are colored in black and green, respectively, and mutations are highlighted in cy
See also Figure S4.
Structure 23, 40In contrast, growth of the yeastmutantC52F is slightly impaired
at 30C and strongly reduced at 37C (Figures 2A and S2A). It
is devoid of any ChT-L activity toward the Z-GGL-pNA substrate
(Figure 2B) and cleavage rates of Suc-LLVY-AMC in vitro
are about 80% lower than withWT yCPs (Figure S2B). The reduc-
tion in proteolytic activity is accompanied by 10-fold reduced
affinities forbortezomib,carfilzomib,andONX0914(Figure3).This
considerable cross-resistance to a0,b0-epoxyketones suggests aoteasomes (yCPs)
ir apo form (left). Structural changes upon bortezomib docking are illustrated by
und (yellow) states (right). Carbon atoms of the active site Thr1 and bortezomib
an.
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general way of preventing substrate and inhibitor binding, which
we further examined by X-ray crystallography. Binding of most
proteasome inhibitors to the active site Thr1 triggers rotation of
Met45. Hereby, the P1 leucine side chains of bortezomib and car-
filzomib cause smaller movements than the larger phenylalanine
side chain of ONX 0914. Incorporation of Phe52 instead of
cysteine, however, interferes with this movement and creates
an additional steric barrier to compoundswith bulky P1 sites (Fig-
ure 4I). Indeed, co-crystal structures revealed that bortezomib
and carfilzomib (both Leu in P1) but not ONX 0914 (Phe in P1)
bind to the active site Thr1 of the C52F mutant yCP (Figures 4I
and S4I). This observation is consistent with the low inhibition
potential of ONX 0914 for the C52F yCP.
To further confirm that small hydrophobic P1 inhibitor side
chains are less affected by the C52F mutation, we tested the
affinity for the nonpeptide b-lactone inhibitor clasto-lactacystin,
also known as omuralide (4, Figure S1) (Fenteany et al., 1995).
Its small P1 isopropyl group has previously been proven to leave
the position of Met45 unchanged (Groll et al., 1997; List et al.,
2014). Thus, its binding capacity should not be reduced by
the mutation C52F. In fact, the natural b-lactone is much
more potent toward the C52F mutant yCP (IC50 0.543 mM ±
0.045 mM; Figure S3) than prevalent proteasome inhibitors. How-
ever, the affinity of omuralide is still reduced by a factor of five
compared with WT yCPs (IC50 0.112 mM ± 0.010 mM; Figure S3).
Structural superposition of the WT and mutant proteasome sub-
unit b5 in their ligand-free states illustrates that Phe52 pushes
Met45 into the S1 pocket (1 A˚ shift of the sulfur atom; Figure 4I)
and thereby decreases its size. Consequently, binding of omur-
alide atypically necessitates slight movements of Met45 (0.5 A˚
shift of the sulfur atom; Figure S4I), and its affinity for the b5
active site is thus impaired.
DISCUSSION
Mutagenesis as a Drug Escape Strategy
We provide here a systematic structural and biochemical exam-
ination of mutations that convey resistance to proteasome inhib-
itors. In total, 49 crystal structures and 38 IC50 values of 11
different mutant yCPs were analyzed and a general overview of
their mechanism of resistance is provided. These adaptivemuta-
tions in the b5 binding site of the proteasome allow tumor cell
cultures to escape the cytotoxic effects of the boronic acid inhib-
itor bortezomib (Kale and Moore, 2012). Even though evidence
for the clinical relevance of these mutations is still lacking, their
existence has to be considered for several reasons. First, the
mutation frequency in cancer cells is higher than in healthy tis-
sues (Loeb, 2011), thus likely favoring the emergence of mutant
proteins and, second, adaptivemutations in the drug binding site
of enzymes arewell known from other anticancer remedies, such
as imatinib, an inhibitor of the tyrosine kinase BCR-ABL (O’Hare
et al., 2007). Hence, mutagenesis of target proteins generally
constitutes an effective strategy to evade the drug-mediated
selection pressure.
Carfilzomib, the Best-in-Class Compound
In agreement with previous studies (Oerlemans et al., 2008; Ver-
brugge et al., 2012), we found a marked cross-resistance of bor-
tezomib-insensitive CPs to the a0,b0-epoxyketones carfilzomib414 Structure 23, 407–417, February 3, 2015 ª2015 Elsevier Ltd All rand ONX 0914, indicating that the mechanisms of resistance
are independent of the electrophilic inhibitor head group. Among
the three covalently acting proteasome inhibitors tested, carfil-
zomib could overcome mutation-mediated resistance best and
thus represents the most potent proteasome inhibitor available
to date. As revealed by our X-ray structure, the enhanced
potency of carfilzomib likely results from its irreversible mode
of action as well as from its tetrapeptide moiety, which signifi-
cantly improves anchoring in the b5 substrate binding channel
compared with the dipeptide bortezomib and the tripeptide
ONX 0914. In summary, the enhanced stabilization of carfilzomib
in the substrate binding channel enables its high-affinity binding
to both WT and drug-resistant CPs.
Aspects of Activity and Inhibition of Mutant CPs
The Hill coefficients, a measure of cooperativity and steepness
of dose-response curves, vary greatly depending on the type
of CP and inhibitor used. Although no striking changes were de-
tected for ONX 0914, carfilzomib binding is altered in almost all
mutants compared with WT. For bortezomib, the steepness of
the inhibition curves positively correlates with the factor of resis-
tance (Figure 3). Preferentially, mutants with pronounced growth
or activity defects (A49T/V, A49T_A50V M45V/I, C52F) display
higher cooperativity for bortezomib binding. Numerous previous
studies on the proteasome suggested an allosteric coupling of
the active sites. Support for communication between the two
b5 subunits within one y/cCP by conformational changes has
recently been provided by structural data (Arciniega et al.,
2014). Themutations in the substrate binding channel may affect
this intersubunit network and ultimately the Hill coefficients in the
inhibition curves. The experimental setup was identical for all
mutants and substrate consumption before the end of the assay
as well as changes in enzyme concentration or quality can be
ruled out as reasons for the observed variations in cooperativity.
Activity assays revealed that most mutations markedly reduce
both inhibitor binding and cleavage of the b5-specific model
substrates Z-GGL-pNA and Suc-LLVY-AMC. Although no turn-
over of the Z-GGL-pNA substrate was observed in the overlay
assays for certain mutants (Figure 2B), residual ChT-L activity
was detectable for all yCP variants with the standard fluorogenic
substrate Suc-LLVY-AMC (Figure S2B). Due to the lack of side
chains, in particular of the P3 site, the Z-GGL-pNA substrate is
insufficiently stabilized in the b5 active site and consequently
poorly processed compared with Suc-LLVY-AMC (Kisselev
and Goldberg, 2005). Furthermore, fluorescence-based activity
measurements are more sensitive than chromogenic assays,
which provide only rough assessment of proteasome activities.
To clarify whether the reduction in activity is a result of insuffi-
cient autolytic removal of the b5 propeptide or disruption of the
active site integrity, we conducted structural analyses. These
studies confirmed that all mutants are fully matured; however,
it cannot be excluded that certain aa substitutions may delay
propeptide processing, thereby causing proliferation defects.
As proven by inhibitor complex structures, the b5 mutant active
sites are functionally intact and reactive, suggesting that the al-
terations restrict substrate and ligand binding to a degree that
still enables the cell to survive, albeit at lower proliferation rates.
Reduction of growth rates has not been described for human cell
lines encoding mutations in the b5c subunit. While mammalianights reserved
cells are capable of expressing the immunosubunits b5i and b1i,
which also exert chymotrypsin-like activity and may balance fail-
ure of the b5c subunit, yeast bears only one type of CP and de-
fects in its activity immediately result in severe phenotypes.Biological Relevance of Bortezomib Resistance-
Conferring Mutations
The crystal structures visualize three distinct ways to efficiently
escape proteasome inhibition: (1) narrowing of the active site
entrance (Ala49 mutants; Figure 5A); (2) disruption of stabilizing
interactions with ligands (Ala49 and M45 mutants; Figure 5B);
(3) prevention of essential conformational changes within the
enzyme (C52Fmutant). Strikingly, some of themutations causing
these effects, namely M45I, M45T, A49V, and A49S, are also
naturally occurring and hence of certain yet unknown biological
relevance. The archaea Thermoplasma acidophilum andArcheo-
globus fulgidus, e.g., encode Ile45 and Thr45, respectively, in
their proteolytically active b subunit. Furthermore, Thr45 is also
encoded in the mammalian tCP subunit b5t and supposed to
contribute to altered cleavage preferences. In conclusion, varia-
tions ofMet45donot interferewith proteasomeactivity per sebut
may be adapted for special biological functions.
The b5 mutation A49V (also known as pre2-2) has been iden-
tified in a screen for proteasome mutants defective in ChT-L ac-
tivity (Heinemeyer et al., 1991, 1993). Notably, Val49 is by nature
part of all archaeal proteasomal b subunits (Figure S5C) (Groll
et al., 2003; Lo¨we et al., 1995) and differences in the dynamics
or cleavage preferences of proteasomes from archaea and
mammals may account for this strict requirement. However,
Val49 might also serve to restrict the proteolytic turnover of
the 14 active sites of archaeal CPs to a certain level, whereas
eukaryotic CPs bear only six catalytic centers. Furthermore,
Val49 has been implicated in the self-resistance of the marine
actinobacterium Salinospora tropica to its secondary metabolite
salinosporamide A, a highly potent natural proteasome inhibitor
(Kale et al., 2011; Kale and Moore, 2012). Ser49 is strictly
conserved in the mammalian tCP subunit b5t and might
contribute to the unique cleavage preferences of this protea-
some type (Murata et al., 2007). Although Ser49 also mediates
drug resistance, only Thr and Val were identified in cell cultures.
This might be due to the fact that a single point mutation suffices
to substitute Ala49 with Thr or Val, whereas two base pair ex-
changes are required for Ser.
Here, we provide a systematic high-throughput analysis of
mutant 20S proteasomes for their effects on cell survival, proteo-
lytic activity, inhibitor binding, and structural integrity. The results
are valuable for understanding resistance to proteasome inhibi-
tion as well as the sophisticated architecture of the eukaryotic
proteasomal active sites in general. This study illustrates the
impressive evolutionary adaption of the proteasomal interdigi-
tating aa network to the specific requirements of eukaryotes
and exemplifies the biological consequences of its disruption
by marginal single point mutations.EXPERIMENTAL PROCEDURES
Gene Mutagenesis
The plasmid pRS315-PRE2 (LEU2 selection marker) (Heinemeyer et al., 1993)
served as a template for gene mutagenesis. pre2 gene variants were createdStructure 23, 40either directly by QuikChange mutagenesis or by recombinant PCR tech-
niques and subsequently cloned into the plasmid pRS315 (for primer se-
quences see Table S2). Introduction of the respective mutations was
confirmed by Sanger sequencing (GATC Biotech).
Yeast Transformation and Plasmid Shuffling
Mutant S. cerevisiae strains were created by the plasmid shuffle procedure
(Sikorski and Boeke, 1991). The haploid yeast strain YWH20a (pre2D::HIS3
[pRS316-PRE2]), which is chromosomally deleted in its WT PRE2 gene and
instead carries a WT gene copy on the pRS316 URA3 episome (Heinemeyer
et al., 1997), was transformed by the created mutant pRS315-pre2 plasmids
or by the WT pRS315-PRE2 construct (Gietz and Woods, 2002). Transform-
ants were selected on CM (synthetic complete medium) Leu, Ura, His
plates, later grown on yeast extract peptone dextrose (YPD) plates to enable
loss of the URA3 episome and finally exposed to 5-fluoroorotic acid to select
for clones that lost the WT PRE2 copy but retained the mutant one. Due to the
indispensable need for a functional pre2 gene for yeast survival, no further se-
lection was required.
Drop Test
Overnight cultures of mutant and WT (WCG4a and pre2D::HIS3 [pRS315-
PRE2]) yeast strains were grown in YPD at 30C. Their optical density was
determined at 600 nm and appropriate serial dilutions in YPD medium were
prepared. Total cell numbers of 10,000, 1,000, 100, and 10 were spotted on
YPD plates and grown for 2–3 days at 30C or 37C, respectively, to evaluate
proliferation rates by colony size as well as survival rates by colony numbers.
In Situ Test for Chymotrypsin-like Activity
Yeast strains, grown as patches on YPD plates, were replica plated on a sterile
filter paper lying on a YPD plate and grown for an additional 2 days at 30C.
Cells were lysed by treating the filter paper with 10 ml of chloroform for
15 min and subsequently covered with 10 ml of overlay solution (1% [w/v]
agar, 50 mM Tris-HCl [pH 8.0], 300 ml of 10 mM Z-Gly-Gly-Leu-pNA [Bachem]
substrate in DMSO). After incubation for 3 hr at 30C, the following incubation
stepswere carried out: 10ml of 0.1% (w/v) sodium nitrite solution in 1MHCl for
5 min; 10 ml of 0.5% (w/v) ammonium sulfamate solution in 1 M HCl for 5 min;
10ml of 0.05% (w/v)N-(1-naphthyl)ethylenediamine solution in 47% (v/v) EtOH
for 10–30 min. Cells with normal ChT-L activity became pink, while defective
ones were less colored.
Cell Culture
Mutant yeast strains were grown in 18 l YPD cultures for 2 days at 30C. Cells
were harvested by centrifugation for 15min at 5,000 g and frozen at –20C until
further use.
Protein Purification
Purification of mutant yCPs was performed as described previously for WT
CPs (Gallastegui and Groll, 2012).
Substrate and Inhibitor Stock Solutions
All peptide substrates were purchased from Bachem. Bortezomib was pur-
chased from Selleck Chemicals, carfilzomib from Active Biochemicals, ONX
0914 from MedKoo Biosciences, and clasto-lactacystin b-lactone (omuralide)
from Calbiochem. All substrates and inhibitory compounds were dissolved in
DMSO and stored as 20 mM stock solutions at –20C.
Inhibition Assays
Protein concentrations of purified yCP variants were determined spectropho-
tometrically. The absorption at 280 nm was corrected for the buffer spectrum
(100mMTris-HCl [pH 7.5]). Taking into account the extinction coefficient of the
yCP, protein concentrations were calculated via the Beer-Lambert law.
Purified yCPs (in 100mMTris-HCl [pH 7.5]) weremixedwith DMSOas a con-
trol or serial dilutions of inhibitor and incubated for 45min at room temperature.
The final concentration of yCP was 66 nM. After addition of the peptide sub-
strate Suc-Leu-Leu-Val-Tyr-AMC to a final concentration of 200 mM and incu-
bation for 1 hr at room temperature, proteolysis was stopped by diluting the
samples 1:10 in 20 mM Tris-HCl (pH 7.5). The AMC molecules released by re-
sidual proteasomal activity were measured in triplicate with a Varian Cary7–417, February 3, 2015 ª2015 Elsevier Ltd All rights reserved 415
Eclipse Fluorescence Spectrophotometer (Agilent Technologies) at lexc =
360 nm and lem = 460 nm. Relative fluorescence units were normalized to
the DMSO-treated control. The calculated residual activities were plotted
against the logarithm of the applied inhibitor concentration and fitted to
the equation Y = bottom + (top – bottom)/(1 + 10(logIC50  X) 3 HillSlope) (X is
the logarithm of the inhibitor concentration; Y is the residual enzymatic activity;
log(inhibitor) versus response – variable slope (four parameters); GraphPad
Prism 5). The IC50 value, the ligand concentration that leads to 50% inhibition
of the enzymatic activity, was deduced from the fitted data.
Crystallization and Structure Determination
Purified yCP mutants were crystallized as described for WT yCPs (Gallastegui
and Groll, 2012). Inhibitor complex structures were obtained by incubating
crystals in 5 ml of cryobuffer (20 mM magnesium acetate, 100 mM MES
(2-[N-morpholino]ethanesulfonic acid) [pH 6.8], and 30% (v/v) MPD (2-
methyl-2,4-pentanediol) supplemented with bortezomib, carfilzomib, or ONX
0914 at a final concentration of 1.5 mM).
Diffraction data were collected at the Paul Scherrer Institute, SLS, Villigen,
Switzerland, at a wavelength of l = 1.0 A˚ at the beamline X06SA and processed
as previously published (Gallastegui and Groll, 2012). Evaluation of reflection
intensities and data reduction were performed with the program package
XDS (Kabsch, 2010). Molecular replacement using the coordinates of the
yCP (PDB entry code 1RYP [Groll et al., 1997]) was carried out by rigid body
and anisotropic TLS (translation/libration/screw) refinements with REFMAC5
(Vagin et al., 2004). MAIN (Turk, 2013) and COOT (Emsley et al., 2010) served
as model building software. The coordinates yielded excellent Rcrys, Rfree,
rmsd bond and angle values as well as good stereochemistry from the
Ramachandran plot and have been deposited in the RCSB Protein Data
Bank (Table S1).
ACCESSION NUMBERS
Coordinates and structure factors have been deposited in the RCSB Protein
Data Bank. The entry codes are provided in Table S1.
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